CoChat

Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy

Open access

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

Monoclonal antibodies targeting immune checkpoints are gaining ground in the treatment of melanoma and other cancers, and considerable effort is made to identify biomarkers predicting the efficacy of these therapies. Our retrospective study was performed on surgical tissue samples (52 lymph nodes and 34 cutaneous/subcutaneous metastases) from 30 patients with metastatic melanoma treated with ipilimumab. Using a panel of 11 antibodies against different immune cell types, intratumoral immune cell densities were determined and evaluated in relation to response to ipilimumab treatment and disease outcome. For most markers studied, median immune cell densities were at least two times higher in lymph node metastases compared to skin/subcutaneous ones; therefore, the prognostic and predictive associations of immune cell infiltration were evaluated separately in the two groups of metastases as well as in all samples as a whole. Higher prevalence of several immune cell types was seen in lymph node metastases of the responders compared to non-responders, particularly FOXP3+ cells and CD8+ T lymphocytes. In subcutaneous or cutaneous metastases, on the other hand, significant difference could be observed only in the case of CD16 and CD68. Associations of labeled cell densities with survival were also found for most cell types studied in nodal metastases, and for CD16+ and CD68+ cells in skin/s.c. metastatic cases. Our results corroborate the previous findings suggesting an association between an immunologically active tumor microenvironment and response to ipilimumab treatment, and propose new potential biomarkers for predicting treatment efficacy and disease outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-017-2072-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Balatoni T, Mohos A, Sebestyén T, Varga A, Oláh J, Lengyel Z, Emri G, Liszkay G, Ladányi A (2017) Tumor-infiltrating immune cells as potential predictive markers of response to treatment and survival in metastatic melanoma patients receiving ipilimumab. J Transl Med 15(Suppl 1):8 (O7, Abstract)

Cited by

Metadata

Authors
Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., & Ladányi, A.
Affiliations
  • National Institute of Oncology (HU)
  • Semmelweis University (HU)
  • Szent János Kórház (HU)
  • University of Szeged (HU)
  • University of Pecs (HU)
  • University of Debrecen (HU)
  • Országos Korányi Tbc és Pulmonológiai Intézet (HU)
Corresponding author
Ladányi, Andrea
Venue
Cancer Immunology, Immunotherapy
Published
2017-10-07
Volume
67
Issue
1
Pages
141-151
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2761875085
Cited by
76
References
34
Citations by year
2026: 1 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 18 · 2020: 13 · 2019: 9 · 2018: 3 · 2017: 1
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
Funders
  • National Research, Development and Innovation Office (K105132, K116295)
  • European Union (GINOP_2.3.2-15-2016-00020)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
metastatic melanoma, ipilimumab, tumor-infiltrating immune cells, predictive biomarkers, prognostic factors, immune checkpoint inhibitors, Foxp3+ regulatory T cells, CD8+ T cells, CD16+ natural killer cells, CD68+ macrophages, lymph node metastasis, tumor microenvironment, treatment response, survival
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Adult, Aged, Female, Humans, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Retrospective Studies, Biomarkers, Lymphocytes, Tumor-Infiltrating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.